BMJ5d
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
Objectives Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA. Methods FOREMOST (NCT03747939) ...
BMJ20h
Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations
Objectives Although shared decision making (SDM) is advocated in rheumatoid arthritis (RA) treatment, it is largely unclear when, how and to what extent SDM is applied in routine clinical care of ...
BMJ17d
Protein kinase R is highly expressed in dermatomyositis and promotes interferon-beta-induced muscle damage
Objectives Dermatomyositis (DM) has been consistently linked to the type I interferon (IFN-I) pathway. However, the precise pathogenesis remains incompletely elucidated. We aimed to explore potential ...
BMJ2d
Low-ratio somatic NLRC4 mutation causes late-onset autoinflammatory disease
Objectives We aim to investigate the genetic basis of a case of late-onset autoinflammatory disease characterised by arthritis, recurrent fever and skin rashes. Methods We performed whole-exome/genome ...
BMJ3d
Defining refractory rheumatoid arthritis
While biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed outcomes of people with rheumatoid arthritis (RA), a proportion of patients are refractory to multiple bDMARDs.
BMJ11d
Development and validation of a methotrexate adherence assay
Correspondence to Dr James Bluett, Versus Arthritis Centre for Genetics and Genomics, Centre for Musculoskeletal Research, The University of Manchester, Manchester M13 9PT, UK; ...
BMJ3d
Oral steroid in the treatment of carpal tunnel syndrome
Dr S M Wong, Department of Medicine, Prince of Wales Hospital, 30–32 Ngan Shing Street, Shatin, New Territories, Hong Kong, Special Administrative Region China If you wish to reuse any or all of this ...
BMJ12d
Instrument selection for the ASAS core outcome set for axial spondyloarthritis
23 National Institute for Health Research, University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK Objectives To define the ...
BMJ6d
Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse
1 Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody ...
BMJ6d
Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications
Objective Autoantibodies against antigens carrying distinct post-translational modifications (PTMs), such as citrulline, homocitrulline or acetyllysine, are hallmarks of rheumatoid arthritis (RA). The ...
BMJ4d
Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis
Objectives Various hypotheses exist for the explanation of placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis with IR to methotrexate (MTX). We ...
BMJ9d
From real-world electronic health record data to real-world results using artificial intelligence
With the worldwide digitalisation of medical records, electronic health records (EHRs) have become an increasingly important source of real-world data (RWD). RWD can complement traditional study ...